6696 Stock Overview
Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Lin BioScience, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NT$100.50 |
52 Week High | NT$205.00 |
52 Week Low | NT$99.60 |
Beta | 0.0044 |
1 Month Change | -11.06% |
3 Month Change | -14.47% |
1 Year Change | -45.53% |
3 Year Change | -36.39% |
5 Year Change | 164.47% |
Change since IPO | 105.06% |
Recent News & Updates
Shareholder Returns
6696 | TW Biotechs | TW Market | |
---|---|---|---|
7D | 0.5% | 0.4% | 2.7% |
1Y | -45.5% | -22.1% | 25.7% |
Return vs Industry: 6696 underperformed the TW Biotechs industry which returned -22.1% over the past year.
Return vs Market: 6696 underperformed the TW Market which returned 25.8% over the past year.
Price Volatility
6696 volatility | |
---|---|
6696 Average Weekly Movement | 4.0% |
Biotechs Industry Average Movement | 4.1% |
Market Average Movement | 4.2% |
10% most volatile stocks in TW Market | 8.0% |
10% least volatile stocks in TW Market | 1.9% |
Stable Share Price: 6696 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6696's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | n/a | n/a | https://www.linbioscience.com |
Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to evaluate safety and efficacy in Dry AMD; LBS-007, a natural non-ATP CDC7 inhibitor for the treatment of cancers; LBS-002, an anti-tubulin to treat primary and metastatic brain tumors; and LBS-009, an oral therapy for the treatment of non-alcoholic fatty liver disease and type 2 diabetes. The company is headquartered in Taipei, Taiwan.
Lin BioScience, Inc. Fundamentals Summary
6696 fundamental statistics | |
---|---|
Market cap | NT$7.89b |
Earnings (TTM) | -NT$518.43m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-15.2x
P/E RatioIs 6696 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6696 income statement (TTM) | |
---|---|
Revenue | NT$0 |
Cost of Revenue | NT$0 |
Gross Profit | NT$0 |
Other Expenses | NT$518.43m |
Earnings | -NT$518.43m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -6.61 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did 6696 perform over the long term?
See historical performance and comparison